The board of directors (the "Directors") of the Sinco Pharmaceuticals Holdings Limited (the "Board") announced shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the "Reporting Period"), which have not been confirmed, reviewed or audited by the Company's auditors or audit committee and may be subject to adjustment, and other information currently available to the Group's management, the Group is expected to record a net profit attributable to equity holders of the Company for the Reporting Period of approximately RMB 19.6 million, representing a decrease of approximately RMB 42.3 million
or approximately 68.3%, as compared to the net profit attributable to equity holders of the Company of approximately RMB 61.9 million for the six months ended 30 June 2022.